Our top pick for
Biomea Fusion Inc is a biotechnology business based in the US. Biomea Fusion shares (BMEA) are listed on the NASDAQ and all prices are listed in US Dollars. Biomea Fusion employs 20 staff and has a market cap (total outstanding shares value) of 0.00.
|Latest market close||$11.74|
|52-week range||$9.72 - $22.22|
|50-day moving average||$11.94|
|200-day moving average||$14.71|
|Wall St. target price||$26.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.23|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-13)||4.92%|
|1 month (2021-09-20)||13.43%|
|3 months (2021-07-20)||-13.93%|
|6 months (2021-04-20)||-30.08%|
|1 year (2020-10-16)||N/A|
|2 years (2019-10-16)||N/A|
|3 years (2018-10-16)||N/A|
|5 years (2016-10-16)||N/A|
|Gross profit TTM||$0|
|Return on assets TTM||-10.6%|
|Return on equity TTM||-17.49%|
|Market capitalisation||$337.3 million|
TTM: trailing 12 months
There are currently 1.6 million Biomea Fusion shares held short by investors – that's known as Biomea Fusion's "short interest". This figure is 14% up from 1.4 million last month.
There are a few different ways that this level of interest in shorting Biomea Fusion shares can be evaluated.
Biomea Fusion's "short interest ratio" (SIR) is the quantity of Biomea Fusion shares currently shorted divided by the average quantity of Biomea Fusion shares traded daily (recently around 78392.966507177). Biomea Fusion's SIR currently stands at 20.9. In other words for every 100,000 Biomea Fusion shares traded daily on the market, roughly 20900 shares are currently held short.
To gain some more context, you can compare Biomea Fusion's short interest ratio against those of similar companies.
However Biomea Fusion's short interest can also be evaluated against the total number of Biomea Fusion shares, or, against the total number of tradable Biomea Fusion shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Biomea Fusion's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Biomea Fusion shares in existence, roughly 60 shares are currently held short) or 0.1141% of the tradable shares (for every 100,000 tradable Biomea Fusion shares, roughly 114 shares are currently held short).
A SIR above 20% would generally be considered very high, pointing to a pessimistic outlook for the share price, with a discouraging number of investors currently willing to bet against Biomea Fusion.
Find out more about how you can short Biomea Fusion stock.
We're not expecting Biomea Fusion to pay a dividend over the next 12 months.
Biomea Fusion, Inc. , a biopharmaceutical company, focuses on the discovery, development, and commercialization of irreversible small molecules to treat patients with genetically defined cancers. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective irreversible inhibitor of MENIN, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was founded in 2017 and is headquartered in Redwood City, California. .
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.